Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gadofosveset

Next Previous
Drug Profile

Gadofosveset

Alternative Names: Ablavar; AngioMARK; Gadofosveset-trisodium; MS 325; MS 32520; Vasovist; ZK 236018

Latest Information Update: 25 Sep 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Massachusetts General Hospital
  • Developer EPIX Pharmaceuticals
  • Class Acetates; Amines; Cyclohexanes; Diagnostic agents; Organometallic compounds; Phosphates
  • Mechanism of Action Magnetic resonance imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cardiovascular disorders

Most Recent Events

  • 20 Nov 2009 The CHMP of the European Medicines Agency makes recommendations to minimise the risk of nephrogenic systemic fibrosis
  • 08 Oct 2009 Adverse events data from post-marketing review released by Lantheus Medical Imaging
  • 07 Apr 2009 Gadofosveset out-licensed to Lanthus Medical Imaging in the US, Puerto Rico, Canada and Australia ,

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top